missing translation for 'onlineSavingsMsg'
Learn More
Learn More
IgG1 Rat anti-Mouse, Brilliant Violet 650, Clone: X56, BD Optibuild™
Beschreibung
The X56 monoclonal antibody specifically binds to mouse IgG1 of Igh-C[a] /and Igh-C[b] /haplotypes. It does not crossreact with other Ig isotypes.
The antibody was conjugated to BD Horizon™ BV650 which is part of the BD Horizon Brilliant™ Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405nm and an acceptor dye with an Em Max at 650nm. BD Horizon BV650 can be excited by the violet laser and detected in a filter used to detect APC-like dyes (eg, 660/20nm filter). Due to the excitation and emission characteristics of the acceptor dye, there will be spillover into the APC and Alexa Fluor™ 700 detectors. However, the spillover can be corrected through compensation as with any other dye combination. BV650 is a tandem fluorochrome of BD Horizon BV421 and an acceptor dye with an emission maximum at 650 nm. Due to the excitation and emission characteristics of the acceptor dye, there will be spillover into the APC and Alexa Fluor™ 700 detectors. BV650 will have moderate spillover into the BD Horizon™ BV711 detector.
Spezifikation
Spezifikation
| Antigen | IgG1 |
| Klassifikation | Monoclonal |
| Klon | X56 |
| Konzentration | 0.2mg/mL |
| Konjugat | Brilliant Violet 650 |
| Zusammensetzung | Aqueous buffered solution containing ≤0.09% sodium azide. |
| Gen-Alias | Igh-4, Ighg1, Immunoglobulin heavy constant gamma 1 |
| Wirtsspezies | Rat |
| Immunogen | Mouse IgG1, κ Antibody |
| Reinigungsverfahren | Affinity Purified |
| Mehr anzeigen |
Name des Produkts
Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.
Haben Sie Verbesserungsvorschläge?